SWOG 1937: A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Start Date: February 23, 2021

IRB Number: https://clinicaltrials.gov/ct2/show/NCT04579224

Condition/Disease: Cancer - Kidney, Cancer - Bladder

Principal Investigator: Ding Wang, MD

Purpose of Research: CANCER, KIDNEY CANCER, KIDNEY, BLADDER CANCER, BLADDER, URETER, UROTHELIAL, UROTHELIAL CANCER

Status: In Progress

Phone: (313) 916-1784

Filter Results

Consent for Cookie Use